Israeli privately-held tech companies raised $12.2 billion in 2024, up 31% from 2023, Start-Up Nation Central (SNC) reported today. Of this figure, $10.6 billion was officially reported by the ...

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

Teva Pharmaceutical ( NYSE: TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) on January 31. The company’s shares ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE:TEVA). And retail traders should know. We noticed this today when the trades showed up on ...

Teva Pharmaceutical Industries Limited has a 12-month low of $11.83 and a 12-month high of $22.80. The stock has a market capitalization of $19.07 billion, a PE ratio of -11.61, a price-to ...

Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after ...